Federal contractor · LOUISVILLE, CO

BOLDER BIOTECHNOLOGY INC

No contract obligations recorded for BOLDER BIOTECHNOLOGY INC in FY2026. Since FY2021: $3.3M. Its largest customer was National Institutes of Health ($0).

Obligations · FY2026
$0
New awards
1
Sole-source
—
Single offer
—
UEI
CJ6GFX2TU3J4
Small business
Open in the contracts explorerRelationship graph

Spending by fiscal year

Obligations per federal fiscal year (October–September).

  1. 249.9KFY2021
  2. 0FY2022
  3. 1.7MFY2023
  4. 1.4MFY2024
  5. 0FY2025
  6. 0FY2026

Top buying agencies

Obligations in FY2026.

  1. National Institutes of Health$00.0%
    1 awards

What was bought · Where the work was performed

Obligations in FY2026.

What was bought

Where the work was performed

Integrity signals

Shares of the year's obligations, next to the country's.

Largest awards

  1. ADVANCED DEVELOPMENT OF BBT-059 AS A RADIATION MEDICAL COUNTERMEASURE FOR DOSING UP TO 48H POST EXPOSURE"$3.1M
    National Institutes of Health· Boulder County, CO· Research & development· Jun 29, 2023 – Mar 27, 2026· 75N93023C00011

Federal grants & assistance received

Grants, loans (counted at their subsidy cost), direct payments and insurance, by fiscal year of the action (USAspending.gov, FABS). Reported apart from contracts and never added to them.

BOLDER BIOTECHNOLOGY INC received $0 in federal assistance in FY2026, on 2 actions (0 new awards).

Assistance · FY2026
$0
New awards
0
Actions
2
Since FY2021
$2.3M

Assistance by fiscal year

  1. 300KFY2021
  2. 0FY2022
  3. 1MFY2023
  4. 1MFY2024
  5. 0FY2026

Largest awards

  1. NOVEL DRUG COMBINATIONS FOR IMPROVING SURVIVAL FROM ACUTE RADIATION SYNDROME WHEN ADMINISTERED 48 HOURS POST- IRRADIATION - ABSTRACT. BONE…$1.7M
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· May 23, 2023 – May 14, 2026· R44AI142909
  2. IMPROVING SURVIVAL FROM BURKHOLDERIA PSEUDOMALLEI AND OTHER PATHOGENIC INTRACELLULAR BACTERIA - ABSTRACT. BURKHOLDERIA PSEUDOMALLEI (BPM)…$295.9K
    93.855 · Allergy and Infectious Diseases Research· National Institutes of Health· Project grant· Jan 23, 2024 – Feb 19, 2026· R43AI181293

Source: Federal financial assistance transactions (Financial Assistance Broker Submission) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 8, 2026, loaded Oct 8, 2026 · FY2021–FY2026.

Subawards

Matched by Unique Entity ID: the first-tier subawards this organization reported as a prime recipient, and those primes reported paying it.

As a prime: who it pays · FY2026

No subawards reported as a prime in FY2026.

As a sub-recipient: who pays it · FY2026

No subawards reported to it in FY2026.

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 9, 2026, loaded Oct 9, 2026 · Subawards loaded from FY2021.

Teaming partners

Companies this company reported paying, primes that reported paying it, from FFATA subaward reports.

Companies it pays

No subawards reported to other companies.

Primes that pay it

1 company · $31.8K reported

  1. TRUSTEES OF INDIANA UNIVERSITY$31.8K
    INDIANAPOLIS, IN · 1 subaward

Primes report first-tier subawards of $30,000 or more themselves, and many go unreported (GAO-24-106214). Reporting moved from FSRS to SAM.gov in March 2025 and fewer sub-contracts have been reported since. Amounts are what primes reported; they are never added to prime award totals.

Source: Subawards (first-tier sub-contracts and sub-grants reported under FFATA) (U.S. Department of the Treasury, USAspending.gov (reports filed in SAM.gov, formerly FSRS)), data current to Oct 9, 2026, loaded Oct 9, 2026 · Subawards loaded from 2021.

Competitors

Companies that win from the same buyers in the same markets: obligations by agency and industry compared over the last three fiscal years.

Compared on 1 market (agency × industry), FY2024–FY2026.

  1. PLURI BIOTECH LTD$1.4M
    HAIFA, ISR · 99% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  2. ASELL, LLC$1.5M
    OWINGS MILLS, MD · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services
  3. BIOLOGICAL MIMETICS, INC.$1.5M−100% in FY2026
    FREDERICK, MD · 100% of this company's obligations are in markets they both serveNational Institutes of Health · Scientific research and development services

Showing the top 3 of 25 competitors. Open the profile for the full list.

Who sells to the same buyers in the same markets, not who wins against whom on a given contract. Prime contract obligations by the agency and NAICS code of each award; subawards are never added. A company is a family of legal entities, joined by parent UEI or, in part, by an AI reading of names.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026 · FY2024–FY2026.

Source: Federal contract transactions (Federal Procurement Data System) (U.S. Department of the Treasury, USAspending.gov), data current to Oct 9, 2026, loaded Oct 9, 2026.